0000000000636894

AUTHOR

Tobias Pukrop

showing 5 related works from this author

Effects on Survival and Neurocognitive Functions of Whole-Brain Radiotherapy (WBRT) and Autologous Stem Cell Transplantation (ASCT) as Consolidation …

2016

Abstract Introduction: IELSG32 is an international randomized phase II trial with 2 key clinical questions in pts with PCNSL. The first question focused on optimal induction therapy, and results of the 1st randomization have demonstrated that MATRix combination (methotrexate (MTX), cytarabine (ARAC), thiotepa, rituximab (R)) is associated with significantly better outcome [Ferreri AJ, et al. Lancet Haematol 2016]. The second question addresses the efficacy and neurotolerability of ASCT, as an alternative to WBRT as consolidation. Herein, we report the results of the 2nd randomization (NCT01011920). Methods: HIV-neg pts 18-70 ys and ECOG PS ≤3 with new histology-proven PCNSL and measurable d…

medicine.medical_specialtyIntention-to-treat analysisRandomizationbusiness.industryImmunologyCell BiologyHematologyThioTEPANeutropeniamedicine.diseaseBiochemistry3. Good health03 medical and health sciences0302 clinical medicineQuality of lifeChemoimmunotherapy030220 oncology & carcinogenesisInternal medicineImmunologymedicineClinical endpointRituximabbusiness030215 immunologymedicine.drugBlood
researchProduct

CD14 is a key organizer of microglial responses to CNS infection and injury

2015

Microglia, innate immune cells of the CNS, sense infection and damage through overlapping receptor sets. Toll-like receptor (TLR) 4 recognizes bacterial lipopolysaccharide (LPS) and multiple injury-associated factors. We show that its co-receptor CD14 serves three non-redundant functions in microglia. First, it confers an up to 100-fold higher LPS sensitivity compared to peripheral macrophages to enable efficient proinflammatory cytokine induction. Second, CD14 prevents excessive responses to massive LPS challenges via an interferon β-mediated feedback. Third, CD14 is mandatory for microglial reactions to tissue damage-associated signals. In mice, these functions are essential for balanced …

0301 basic medicineChemokineToll-like receptorInnate immune systembiologyMicrogliaCD14Proinflammatory cytokine03 medical and health sciencesCellular and Molecular Neuroscience030104 developmental biologymedicine.anatomical_structureImmune systemNeurologyImmunologybiology.proteinTLR4medicineGlia
researchProduct

Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in…

2017

Background The International Extranodal Lymphoma Study Group-32 (IELSG32) trial is an international randomised phase 2 study that addresses two key clinical questions in the treatment of patients with newly diagnosed primary CNS lymphoma. Results of the first randomisation have demonstrated that methotrexate, cytarabine, thiotepa, and rituximab (called the MATRix regimen) is the induction combination associated with significantly better outcome compared with the other induction combinations tested. Here, we report the results of the second randomisation that addresses the efficacy of myeloablative chemotherapy supported by autologous stem-cell transplantation (ASCT), as an alternative to wh…

OncologyAdultMalemedicine.medical_specialtyautologous stem cell transplantationAdolescentLymphomaMedizinprimary CNS lymphoma whole brain radiotherapy autologous stem cell transplantationPhases of clinical researchThioTEPATransplantation AutologousDisease-Free SurvivalCentral Nervous System Neoplasms03 medical and health sciencesYoung Adult0302 clinical medicineAutologous stem-cell transplantationprimary CNS lymphomaChemoimmunotherapyInternal medicineJournal ArticleMedicineHumansAgedManchester Cancer Research CentreDose-Response Relationship Drugbusiness.industryResearchInstitutes_Networks_Beacons/mcrcInduction chemotherapyBrainHematologyMiddle AgedCombined Modality Therapy3. Good healthSurgeryTransplantationRegimenMethotrexate030220 oncology & carcinogenesiswhole brain radiotherapyRituximabFemalebusiness030215 immunologymedicine.drugStem Cell Transplantation
researchProduct

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the firs…

2016

BACKGROUND: Standard treatment for patients with primary CNS lymphoma remains to be defined. Active therapies are often associated with increased risk of haematological or neurological toxicity. In this trial, we addressed the tolerability and efficacy of adding rituximab with or without thiotepa to methotrexate-cytarabine combination therapy (the MATRix regimen), followed by a second randomisation comparing consolidation with whole-brain radiotherapy or autologous stem cell transplantation in patients with primary CNS lymphoma. We report the results of the first randomisation in this Article.METHODS: For the international randomised phase 2 International Extranodal Lymphoma Study Group-32 …

MaleComparative Effectiveness ResearchTransplantation ConditioningGastrointestinal DiseasesDenmarkMedizinKaplan-Meier EstimateDexamethasoneCentral Nervous System NeoplasmsDeath Sudden0302 clinical medicineIntraocular LymphomaGermanyAntineoplastic Combined Chemotherapy ProtocolsMedicineStandard treatmentOptic Nerve NeoplasmsPoisoningRemission InductionCytarabineHematopoietic Stem Cell TransplantationAnemiaHematologyInduction ChemotherapyAcute Kidney InjuryMiddle AgedCombined Modality TherapyMagnetic Resonance Imaging3. Good healthStrokeTreatment OutcomeTolerabilityItaly030220 oncology & carcinogenesischemoimmunotherapyRituximabFemaleNeurotoxicity SyndromesChemical and Drug Induced Liver InjuryRituximabSwitzerlandmedicine.drugMucositismedicine.medical_specialtyLymphoma B-CellNeutropeniaThioTEPAInfectionsTransplantation AutologousDisease-Free Survival03 medical and health sciencesprimary CNS lymphomaChemoimmunotherapyInternal medicineJournal Articleprimary CNS lymphoma chemoimmunotherapyHumansbusiness.industryThrombosismedicine.diseaseThrombocytopeniaUnited KingdomSurgeryTransplantationRegimenMethotrexateHeart InjuriesHyperglycemiaRadiotherapy Adjuvantbusiness030217 neurology & neurosurgeryFebrile neutropeniaThiotepaFollow-Up StudiesThe Lancet. Haematology
researchProduct

Tyrphostin AG126 exerts neuroprotection in CNS inflammation by a dual mechanism

2015

The putative protein tyrosine kinase (PTK) inhibitor tyrphostin AG126 has proven beneficial in various models of inflammatory disease. Yet molecular targets and cellular mechanisms remained enigmatic. We demonstrate here that AG126 treatment has beneficial effects in experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis. AG126 alleviates the clinical symptoms, diminishes encephalitogenic Th17 differentiation, reduces inflammatory CNS infiltration as well as microglia activation and attenuates myelin damage. We show that AG126 directly inhibits Bruton's tyrosine kinase (BTK), a PTK associated with B cell receptor and Toll-like receptor (TLR) signaling. However, BTK …

MicrogliabiologyExperimental autoimmune encephalomyelitisB-cell receptorInflammationmedicine.diseaseNeuroprotectionProinflammatory cytokineCell biologyCellular and Molecular Neurosciencemedicine.anatomical_structureNeurologyImmunologymedicinebiology.proteinBruton's tyrosine kinasemedicine.symptomTyrosine kinaseGlia
researchProduct